GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma

(2021) T. Y. S. Le Large et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies

(2021) Andres Garcia-Sampedro et al.   Journal of Clinical Medicine

GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals

(2021) Stephen L. Abrams et al.   Cells

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future

(2020) Eric S Christenson et al.   LANCET ONCOLOGY

Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution

(2020) Michelle Chan-Seng-Yue et al.   NATURE GENETICS

Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy

(2020) Panagiotis Sarantis et al.   World Journal of Gastrointestinal Oncology

Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer

(2020) Li Ding et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors.

(2020) Benedito A. Carneiro et al.   JOURNAL OF CLINICAL ONCOLOGY

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

(2020) Holly Brunton et al.   Cell Reports

A Phase 2 Study of AMO-02 (tideglusib) in Congenital and Childhood Onset Myotonic Dystrophy Type 1 (DM1)

(2020) Joseph Horrigan et al.   PEDIATRIC NEUROLOGY

Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets

(2020) Tessa Y.S. Le Large et al.   JCI Insight

Glycogen synthase kinase‐3β participates in acquired resistance to gemcitabine in pancreatic cancer

(2020) Masahiro Uehara et al.   CANCER SCIENCE

Molecular subtypes of pancreatic cancer

(2019) Eric A. Collisson et al.   Nature Reviews Gastroenterology & Hepatology

Pharmacogenetics of treatments for pancreatic cancer

(2019) Btissame El Hassouni et al.   Expert Opinion on Drug Metabolism & Toxicology

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells

(2019) Omidreza Firuzi et al.   Cancers

Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer

(2019) Raffaela Santoro et al.   MOLECULAR CANCER THERAPEUTICS

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer

(2019) Hiroo Kuroki et al.   Scientific Reports

Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression

(2018) Takashi Seino et al.   Cell Stem Cell

Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions

(2018) A. Prasanth Saraswati et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling

(2018) Qingcai Meng et al.   ONCOGENE

Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer

(2018) Siddavaram Nagini et al.   SEMINARS IN CANCER BIOLOGY

Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes

(2018) Gwen Lomberk et al.   Nature Communications

Colorectal cancer cells require glycogen synthase kinase-3β for sustaining mitosis via translocated promoter region (TPR)-dynein interaction

(2018) Firli R.P. Dewi et al.   Oncotarget

Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma

(2018) Laura L. Meijer et al.   ANNALS OF SURGERY

An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice

(2018) Mouad Edderkaoui et al.   GASTROENTEROLOGY

Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity

(2018) Benny Zhitomirsky et al.   Cell Death & Disease

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

(2018) Aslamuzzaman Kazi et al.   Nature Communications

Early detection of pancreatic cancer: Where are we now and where are we going?

(2017) Bin Zhou et al.   INTERNATIONAL JOURNAL OF CANCER

GSK-3β inhibitor 6-bromo-indirubin-3′-oxime promotes both adhesive activity and drug resistance in colorectal cancer cells

(2017) Kunping Liu et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

(2017) Daniela Massihnia et al.   Journal of Hematology & Oncology

Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia

(2017) Li Ding et al.   JOURNAL OF PATHOLOGY

6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells

(2017) Xiaowei Zhang et al.   MOLECULAR THERAPY

Modulating the wnt signaling pathway with small molecules

(2017) Freddi Huan Tran et al.   PROTEIN SCIENCE

Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies

(2017) T.Y.S. Le Large et al.   SEMINARS IN CANCER BIOLOGY

Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer

(2017) E. Giovannetti et al.   SEMINARS IN CANCER BIOLOGY

A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study

(2016) Sukhwinder Kaur et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme

(2016) İlhan Elmaci et al.   BIOCHEMICAL GENETICS

Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer

(2016) James A. McCubrey et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Lithium treatment and cancer incidence in bipolar disorder

(2016) Lina Martinsson et al.   BIPOLAR DISORDERS

Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors

(2016) Lucy Ireland et al.   CANCER RESEARCH

Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy

(2016) Takahiro Domoto et al.   CANCER SCIENCE

Lysosomes as mediators of drug resistance in cancer

(2016) Benny Zhitomirsky et al.   DRUG RESISTANCE UPDATES

An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia

(2016) David A. Rizzieri et al.   LEUKEMIA & LYMPHOMA

GSK-3  Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression

(2016) S. Baumgart et al.   MOLECULAR CANCER THERAPEUTICS

Genomic analyses identify molecular subtypes of pancreatic cancer

(2016) Peter Bailey et al.   NATURE

FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer

(2016) Chiara Caparello et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones

(2015) Hiroshi Yoneyama et al.   ANTI-CANCER DRUGS

Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas

(2015) E. Ben-Josef et al.   CLINICAL CANCER RESEARCH

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

(2015) J. Downward   CLINICAL CANCER RESEARCH

Gemcitabine resistance in pancreatic ductal adenocarcinoma

(2015) Yoav Binenbaum et al.   DRUG RESISTANCE UPDATES

Autophagy in malignant transformation and cancer progression

(2015) L. Galluzzi et al.   EMBO JOURNAL

A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin

(2015) Jhanelle E. Gray et al.   INVESTIGATIONAL NEW DRUGS

Glycogen Synthase Kinase-3 (GSK3) Inhibition Induces Prosurvival Autophagic Signals in Human Pancreatic Cancer Cells

(2015) Benoît Marchand et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(2015) Luping Lin et al.   NATURE GENETICS

Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases

(2015) Eleonore Beurel et al.   PHARMACOLOGY & THERAPEUTICS

GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells

(2015) Aijing Sun et al.   PROSTATE

Unraveling the complexity of autophagy: Potential therapeutic applications in Pancreatic Ductal Adenocarcinoma

(2015) Valentina E. Gómez et al.   SEMINARS IN CANCER BIOLOGY

Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression

(2015) Selvi Kunnimalaiyaan et al.   HPB

Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway

(2015) T Namba et al.   Cell Death & Disease

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon

(2015) Melchiorre Cervello et al.   Oncotarget

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth

(2015) Jan Kroon et al.   Oncotarget

Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance

(2015) Benny Zhitomirsky et al.   Oncotarget

Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells

(2015) Yuki Yoshino et al.   Scientific Reports

Oncogenic KRAS signalling in pancreatic cancer

(2014) S Eser et al.   BRITISH JOURNAL OF CANCER

Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth

(2014) Yvette M Carter et al.   CANCER BIOLOGY & THERAPY

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Lithium Inhibits Tumorigenic Potential of PDA Cells through Targeting Hedgehog-GLI Signaling Pathway

(2014) Zhonglu Peng et al.   PLoS One

Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells

(2014) J-S Zhang et al.   Cell Death & Disease

Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6

(2014) Jennifer L Stamos et al.   eLife

NF- B, an Active Player in Human Cancers

(2014) Y. Xia et al.   Cancer Immunology Research

Identification and analysis of glycogen synthase kinase 3 beta1 interactome

(2013) Xuejuan Gao et al.   CELL BIOLOGY INTERNATIONAL

An Undesired Effect of Chemotherapy

(2013) Sumit Arora et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Role of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation

(2013) Elisa Giovannetti et al.   JNCI-Journal of the National Cancer Institute

GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB

(2013) Deepali Bang et al.   Cancer Discovery

An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β

(2012) Katsuyoshi Miyashita et al.   Anti-Cancer Agents in Medicinal Chemistry

DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells

(2012) Yuriko Saiki et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis

(2012) Min Yu et al.   NATURE

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to TRAIL-Induced Apoptosis

(2012) Shadi Mamaghani et al.   PLoS One

A critical role for autophagy in pancreatic cancer

(2011) Shenghong Yang et al.   Autophagy

Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms

(2011) B. Marchand et al.   CARCINOGENESIS

Regulation of protein stability by GSK3 mediated phosphorylation

(2011) Chong Xu et al.   CELL CYCLE

Pancreatic cancers require autophagy for tumor growth

(2011) S. Yang et al.   GENES & DEVELOPMENT

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer

(2011) Ali Aghdassi et al.   GUT

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

(2011) Juan Manuel Domínguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine

(2011) Takeo Shimasaki et al.   JOURNAL OF GASTROENTEROLOGY

Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1

(2011) Davide Melisi et al.   JNCI-Journal of the National Cancer Institute

Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer

(2011) J-S Zhang et al.   ONCOGENE

Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation

(2011) S. Shin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intracellular pathways underlying the effects of lithium

(2010) Livia Pasquali et al.   BEHAVIOURAL PHARMACOLOGY

The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases

(2010) Hu Zhu et al.   CURRENT GENOMICS

Wnt signal transduction pathways

(2010) Yuko Komiya et al.   Organogenesis

Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy

(2009) Shadi Mamaghani et al.   BMC CANCER

From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3β Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells

(2009) Irina N. Gaisina et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Role of Nuclear Factor κB in Pancreatic Cancer and the Clinical Applications of Targeted Therapy

(2009) Bryan Holcomb et al.   PANCREAS

GSK3β Regulates Differentiation and Growth Arrest in Glioblastoma

(2009) Serdar Korur et al.   PLoS One

GSK3: a multifaceted kinase in Wnt signaling

(2009) Dianqing Wu et al.   TRENDS IN BIOCHEMICAL SCIENCES

Maintenance of Constitutive I B Kinase Activity by Glycogen Synthase Kinase-3 /  in Pancreatic Cancer

(2008) W. Wilson et al.   CANCER RESEARCH

Glycogen Synthase Kinase-3 Inhibition Induces Glioma Cell Death through c-MYC, Nuclear Factor- B, and Glucose Regulation

(2008) S. Kotliarova et al.   CANCER RESEARCH